Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
OUTLIVE: a disruptive non-invasive ultrasound therapy to treat all patients affected with aortic stenosis. (OUTLIVE)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: France
Call: SME instrument (H2020-SMEInst-2018-2020-2, 2018)
Start date: 2019-01-01
End date: 2021-06-30
Duration (months): 30.0
Total project cost (EUR): 3563750.0
EU funding (EUR): 2494625.0
Participants: 1
Project status: CLOSED

Aortic stenosis (AS) is a life-threatening disease caused by the narrowing of the opening of the aortic valve which is the “gateway” from the heart to the body. With age, the aortic valve calcifies and stiffens, leading to poor blood perfusion. It causes heart failure and sudden death. The only medical response to date consists in replacing the aortic valve. It is provided to very sick patients at high risk of sudden death, who represents 25% of all AS patients (6 million in Europe and US). All other affected patients remain untreated. It is an immense unmet medical need. In this context, French medtech Cardiawave has developed a revolutionary solution: Valvosoft, a very innovative real-time image guided medical device for the non-invasive treatment of all AS patients. The device delivers focused high-intensity ultrasounds which repair the aortic valve function. Unlike the current medical solutions, Valvosoft is a non-invasive treatment with low risks, complications and costs. It is a game-changer for patients, physicians and health care establishments because it dramatically changes the way of treating AS throughout the world. It should become a new gold standard: every AS patients will benefit from Valvosoft. Prize-winner of many contests, Cardiawave was created thanks to the combined expertise of an entrepreneur, the Institut Langevin, world leader in ultrasound imaging & therapy and cardiologists from HEGP hospital. The OUTLIVE project will allow Cardiawave to refine current go-to-market strategy and develop an investor ready business plan following CE-mark. Valvosoft clinical safety and efficacy will be demonstrated and reliable trust relation with early-adopters will be established. OUTLIVE will accelerate the scalable Valvosoft commercialisation and enable Cardiawave to become the future leader in non-invasive therapy with expected cumulative revenues exceeding €1.1bn by 2030 and more than 100 new European jobs created.

Keywords: aortic stenosis,aortic valve therapy,non invasive medical device,pulsed cavitational ultrasound,aortic valve reparation
Defining and modulating the stress granule proteome as a therapeutic strategy in Amyotrophic Lateral Sclerosis (StressOME)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Belgium
Call: Individual Fellowships (H2020-MSCA-IF-2018, 2018)
Start date: 2019-05-01
End date: 2021-04-30
Duration (months): 24.0
Total project cost (EUR): 166320.0
EU funding (EUR): 166320.0
Participants: 1
Project status: CLOSED

How do you study a disease with no known cause? Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease. Patients typically die 3-5 years after symptom onset. There is no cure. Finding a cure is hindered by the lack of obvious causes: although 10% of patients show familial inheritance (fALS), 90% of patients exhibit a sporadic form of ALS with no known cause (sporadic ALS, sALS). Almost all ALS patients demonstrate intracellular inclusions of the RNA binding protein TDP-43. However, it is not clear what process allows TDP-43 to aggregate, especially in sALS. This will be the focus of the proposed StressOME project. TDP-43, and other ALS-associated proteins are recruited into stress granules, transient structures that form in response to cellular stresses. Stress granules are thought to constitute a microenvironment with a high local concentration of TDP-43, sufficient to allow its aggregation; however this is prevented in healthy neurons. Therefore, the composition of stress granules may be crucial in the pathogenesis of ALS. To determine whether the dynamics of stress granule assembly and disassembly are different in patient cells, I will derive skin cells from fALS and sALS cases and compare them to age-matched controls. In parallel, I will use a new technique called ‘biotinylation by antibody recognition’ to define the stress granule proteome in sALS and fALS patient cells for the first time. This will allow me to identify candidate genes that modulate stress granule dynamics. I will generate stress granule reporter lines and misexpress candidate proteins, using live cell imaging to determine their effect on the dynamics of stress granules and the recruitment of TDP-43. Candidate genes will also be misexpressed in Drosophila models expressing TDP-43 in order to test their involvement in aggregation and toxicity. Through this approach I will identify novel targets that affect the aggregation of TDP-43 not only in fALS but also sALS.

Keywords: amyotrophic lateral sclerosis
Future Superconducting Magnet Technology (FuSuMaTech)

Framework: Horizon 2020 — Excellent Science
Programme: Future and Emerging Technologies (FET)
Theme: EIC Pathfinder
Destination: Novel ideas for radically new technologies
Action type: Coordination and support actions
Countries involved: Germany,Germany,Spain,Italy,Switzerland,Switzerland,France,France,United Kingdom,United Kingdom,United Kingdom
Call: FET-Open Coordination and Support Actions (H2020-FETOPEN-3-2017, 2017)
Start date: 2017-10-23
End date: 2019-04-22
Duration (months): 18.0
Total project cost (EUR): 501097.5
EU funding (EUR): 501097.5
Participants: 13
Project status: CLOSED

The CERN’s projects, HL-LHC and FCC, will create a big push in the state of the art of High-Field Superconducting magnets in the ten coming years. The performance of superconducting materials such as Nb3Sn and HTS will be developed to yield higher performance at lower costs and the construction materials and techniques will be advanced. At the same time, in the context of Energy’s savings, Industry is experiencing a renewed interest in the domain of industrial superconductivity with fault current limiters, wind generators, electric energy storage, etc. Besides, Medical Research shows a strong interest in High-Field MRI, especially for the brain observation. Considering the social impact of the investment of the HL-LHC project and FCC study, CERN and CEA have established a Working Group on Future Superconducting Magnet Technology (FuSuMaTech).The Working Group has explored a large spectrum of possible synergies with Industry, and has proposed a set of relevant R&D&I projects to be conducted between Academia and industry. To keep the leading position of Europe in the domain, the most efficient way is to support joint activities of Industry and academic partners on the common concerns in view of overcoming the technological barriers. The FuSuMaTech Initiative aims to create the frame of collaborations and to provide common tools to all the EU actors of the domain. The FuSuMatech Initiative is a dedicated and large scale silo breaking programme which will create a sustainable European Cluster in applied Superconductivity. It will enlarge the innovative potential especially in High Field NMR and MRI, opening future breakthroughs in the brain observation. The FuSuMaTech Phase 1 is the first step of the FuSuMaTech Initiative. It is based on practical cases studies and will consist in preparing: 1. The administrative and legal conditions; 2. The detailed description of generic R&D&I actions and of the Technology demonstrators; 3. The funding scheme for the future actions.

Keywords: superconducting magnet technology,pilots and technology demonstrators,quench analysis,cryogenic database,smart diagnostics,helium free,high stress material,high field magnets
Fluorescent Protein-metal oxide NanoParticles for Bio-hybrid Light-Emitting Diodes (FPNP-BioLED)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Germany
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2021-09-01
End date: 2023-08-31
Duration (months): 24.0
Total project cost (EUR): 162806.4
EU funding (EUR): 162806.4
Participants: 1
Project status: SIGNED

White light-emitting diodes (WLEDs) are the future of the artificial illumination promising to reduce 20% of the global electricity consumption in 2025. Nowadays, the main concern of the WLED technology is its sustainable development with respect to the inorganic phosphors (IPs) due to toxicity, environmental hazardousness, scarcity, high costs, and lack of efficient recycling protocols. In this context, bio-hybrid WHLEDs (Bio-WHLED) is emerging as a solid alternative showing how to replace IPs for sustainable fluorescent protein (FPs) embedded in a polymer matrix. In detail, Bio-WHLEDs take advantage of highly emissive blue, green, and red FPs that are stabilized into a rigid or elastomeric polymeric matrix over years under ambient storage and over months under device operation conditions. One of the main challenges towards stable and efficient Bio-WHLEDs consists in the difficult control of spatial distribution of FPs, which implies nonefficient energy transfer processes related to the distance in the polymeric matrix. Moreover, the overheating of Bio-WHLEDs related to the free motion of FP into the polymer matrix leads to the melting of the polymeric matrix and the quick photobleaching of the FPs due to the H-transfer deactivation of the chromophore under continuous excitation. To circumvent these limitations, we propose to develop highly efficient and stable Bio-WHLEDs using single-layered color filters with new white-emitting core-shell FP-nanoparticles (FPNP), in which a white-emitting core in the form of either a mixture of FPs or oligomeric white FPs is protected by a double shell of silica/metal oxide that will simultaneously avoid heat generation (protein motion) and H-transfer processes.

Keywords: bio hybrid light emitting diodes,color down converting filters,fluorescent proteins,inorganic coating,silica nanoparticles
IMPACT GROWTH: EUROPEAN SUPERSTARS FOR FUTURE INTERNET (IMPACT GROWTH)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: Innovation actions
Countries involved: Germany,Spain,Spain,Italy,Finland,Poland,Denmark,Denmark,Mexico
Call: Net Innovation Initiative (H2020-ICT-2016-1, 2016)
Start date: 2016-11-01
End date: 2018-12-31
Duration (months): 26.0
Total project cost (EUR): 6570586.24
EU funding (EUR): 5995021.25
Participants: 17
Project status: CLOSED

IMPACT GROWTH will fund 4 European Superstar Startups (unicorn potential) confirmed by top VC investors and global corporates of 4 smart verticals: cities, digital content, agrifood and factories 48 companies exploiting Future Internet research results will be discovered out of a deal flow of 5.000 startups through 4 OpenCalls. They will join an acceleration programme and will start a crowdfunding track. A “live due diligence” from the acceleration and the market response through the crowd will select the best companies. 4 out of the 48 startups will succeed in reaching the 1.5 million euros crowd funded investment led by the VCs and platforms in the consortium leveraging the 6 million euros of public funding with 6 additional million euros of private investment. The IMPACT GROWTH consortium includes: Mobile World Congress as the reference digital mobile event in the planet; 4 corporates including Danone, Ferrovial, NTT DOCOMO BuonGiorno and MADE (integrates LEGO and Vestas among others); FIWARE Foundation to guarantee the proper exploitation of research results aligning them with other FIWARE initiatives; Accelerace and Kibo Ventures as top VCs; ISDI as leading FIWARE accelerator; FundingBox as leading European startups funding platform; INVESDOR as first global crowdfunded platform with MiFID license and ISDI Mexico that will reinforce EC objectives of globalizing the Future Internet efforts via Mexico and as a pilot on how to engage with Plug & Play and Tel Aviv Go Global joining the project via LoI; PARP, the agency for startups in Poland, will support the consortium via LoI to pilot the adoption of best practices for ESIF purposes under Smart Specialization Strategies for regions. IMPACT GROWTH will help demonstrate that public funded research results with a “continuity” approach (continued support from seed to initial series round) can help top startups become European Superstars and can turn the EU into the EU of "entrepreneurial states".

Keywords: european superstars,future internet,acceleration,technology take up,fiware,knowledge transfer,entrepreneurial discovery,funding support,smart factory,smart cities,smart agri food,d content
Single-cell epigenomics: quantifying epigenetic changes in individual cells using DamID (EpiID)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Integrative Biology: from Genes and Genomes to Systems
Panel description: Genetics, epigenetics, genomics and other ‘omics studies, bioinformatics, systems biology, genetic diseases, gene editing, innovative methods and modelling, ‘omics for personalised medicine
Countries involved: Netherlands
Call: ERC Starting Grant (ERC-2015-STG, 2015)
Start date: 2016-04-01
End date: 2021-09-30
Duration (months): 66.0
Total project cost (EUR): 1500000.0
EU funding (EUR): 1500000.0
Participants: 1
Project status: CLOSED

Phenotypic variation arises from the heritable acquisition of cell-type specific gene-expression programs. Key in understanding cellular specification is to elucidate the epigenetic mechanism that underlies transcriptional heterogeneity. Thus a central question in biology is how cell-to-cell variability in the epigenome contributes to the emergence of phenotypic differences. However, current techniques to profile the epigenome require populations of cells and consequently present ensemble averages of the underlying biology. Therefore, to grasp the molecular concept behind the cellular acquisition of heritable traits it is essential to develop techniques to profile the epigenome at the single-cell level. The advent of single-cell genomics enabled profiling of few epigenetic features and transcriptomics in single cells; however, this toolbox is still very restricted and moreover, to directly correlate the variability in the epigenome to changes in gene-expression activity it is pivotal to device methods to obtain both measurements from the same cell. Therefore, to bridge these shortcomings in the epigenetic toolbox, we plan to develop and apply novel techniques to profile the epigenome in single cells. With this proposal we aim to (1) develop a method to map histone modifications in single cells (2) develop a method to map chromatin organization in single cells (3) develop a method to obtain combined measurements of the epigenome and the transcriptome of the same cell (4) apply these and previously developed single-cell methods, to different biological systems to study how the epigenome contributes to lineage specification. Collectively, the goal of this proposal is to develop a comprehensive single-cell toolbox to take the field to the next (epigenomic) level and to work towards elucidating the molecular mechanism behind cellular specification.

Keywords: single cell genomics,nuclear organization,histone posttranscriptional modifications,damid,lads,pre implantation development
Hybrid Thermoelectrics: From Model to Device (HyThermEl)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Physics
Countries involved: Sweden,Sweden
Call: Individual Fellowships (H2020-MSCA-IF-2017, 2017)
Start date: 2019-01-15
End date: 2021-01-14
Duration (months): 24.0
Total project cost (EUR): 173857.2
EU funding (EUR): 173857.2
Participants: 2
Project status: CLOSED

Europe’s 2030 climate targets make the development of renewable energies a key challenge for researchers across many fields. Thermoelectric generators (TEG) are an emerging technology that promises conversion of the huge amount of waste heat into useful electricity. However, despite big research efforts, they remain niche applications. The reasons are low efficiencies, high costs and scarcity and toxicity of suitable inorganic materials. There is a recent and growing interest in organic-inorganic hybrid TEG. The idea is to combine the advantages of an organic semiconductor (low thermal conductivity, high thermopower) with those of an inorganic nanostructure (high electrical conductivity) by forming a blend of both. Exciting results have very recently been obtained with hybrid materials far outperforming the isolated constituents. This is also a remarkable achievement, given the multi-dimensional parameter space and the absence of a formal framework, forcing progress to be made by mostly heuristic approaches. HyThermEL aims to develop the first predictive, quantitative model for the performance of hybrid thermoelectric systems. By explicitly accounting for morphology, energetics, interfacial effects and the different transport mechanisms of the constituents, the outcome will be physics-based design rules. In a continuous feedback between experiment and theory, these will be employed to fabricate improved hybrid thermoelectric devices while refining the model. The field of hybrid thermodynamics is still in an initial state, so improved fundamental understanding and practical design rules are expected to have great impact on the community. In particular, we are convinced that current hybrid TEG are still far from their upper performance limits and that this project will open new avenues towards competitive TEG.

Keywords: organic semiconductors,hybrid thermoelectrics,kinetic monte carlo model,morphology
Toll-Like Receptor 4 activation and function in diseases: an integrated chemical-biology approach. (TOLLerant)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Innovative Training Networks (ITN)-European Training Networks
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Germany,Italy,Italy,Spain,Spain,Spain,Belgium,Slovenia
Call: Marie Skłodowska-Curie Innovative Training Networks (ITN-ETN) (H2020-MSCA-ITN-2014, 2014)
Start date: 2015-01-01
End date: 2018-12-31
Duration (months): 48.0
Total project cost (EUR): 3122539.38
EU funding (EUR): 3122539.38
Participants: 10
Project status: CLOSED

Based on an international team derived from the COST action BM1003 (www.cost-bm1003.info, 2011-2014) and thus relying on consolidated group interactions and synergies and on a unique combination of chemistry, biology, biophysics, biochemistry and pharmacology expertise, the TOLLerant project aims to gain information on molecular aspects of TLR4 activation and signaling by using synthetic and natural compounds and nanoparticles that interact selectively with some components (mainly MD-2 and CD14) of the TRL4 recognition system. TLR4 is an emerging molecular target related to an impressively broad spectrum of modern day disorders still lacking specific pharmacological treatment. These include autoimmune disorders, chronic inflammations, allergies, asthma, infectious and CNS diseases and cancer. The short-term scientific objective is to develop novel, non-toxic, synthetic and natural TLR4 modulators (agonists or antagonists) and to assess their therapeutic potential on animal models of TLR4-related acute and chronic pathologies that still lack efficient pharmacological treatment. The long-term scientific objective is to develop a new generation of innovative, TLR4-based therapeutics, to be used as vaccine adjuvants, anti-sepsis agents, and anti-inflammatory agents to treat chronic inflammations (allergy, asthma). The training programme will provide Early Stage Researchers (ESR) with broad competences, experience and skills in the cutting-edge, inter-disciplinary research in the field of chemical biology related to the molecular mechanisms of innate immunity and inflammation. During the training, the young researchers will be supported by senior scientists to cultivate their scientific, entrepreneurial and inter-cultural mindset. The non-academic sector will be committed to provide ESRs with entrepreneurship and company management skills, in order to enhance their employability by the private sector or even to motivate them to create own start-up companies.

Keywords: medicinal chemistry,ligand receptor interactions,lipid a,fluorescence,tlr4 signaling,nanoparticles,sepsis,asthma,infectious diseases
Wafers for Automotive and other Key applications using Memories, embedded in Ulsi Processors (WAKeMeUP)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Theme: Public-private partnerships
Destination: Electronic Components and Systems
Action type: Innovation actions
Partnership: ECSEL (Art-187)
Countries involved: Germany,Spain,Germany,Germany,Germany,Germany,Türkiye,France,France,France,France,France,France,France,Czechia
Call: IA (H2020-ECSEL-2017-1-IA-two-stage, 2017)
Start date: 2018-05-01
End date: 2021-08-31
Duration (months): 40.0
Total project cost (EUR): 95048222.0
EU funding (EUR): 24112728.03
Participants: 20
Project status: CLOSED

The WAKEMEUP project objective is to set-up a pilot line for advanced microcontrollers with embedded non-volatile memory, design and manufacturing for the prototyping of innovative applications for the smart mobility and smart society domains. The already defined microcontrollers with 40nm embedded flash technology will be consolidated to build a solid manufacturing platform. Additional developments will be performed for the integration of memory, power management, connectivity, hard security on the same chip. The project will also target the industrialization of the embedded Phase Change Memory (PCM) technology built on top of the FDSOI 28nm logic process pilot line. The development of the ePCM will be driven by the final application requirements as well as decreasing the power consumption. The alternative memory solutions will be also studied as they have different - and complementary - traits in such areas as read/write speed, power and energy consumption, retention and endurance, and device density and benchmarked with the ePCM and the conventional eFlash. Continued advances in materials, device physics, architectures and design could further reduce the energy consumption of these memories. To achieve this goal of generating high value added semiconductor circuits in Europe in a breakthrough leading edge technology the project will deploy all the necessary activities to bring a new technology to an early industrial maturity stage. These activities encompass such developments as: technology enhancements for various specific application requirements such as wide temperature range and reliability, high security requests, high flexibility…, design enablment allowing first time silicon success, prototyping demonstrator products in the different application areas. In the WAKEMEUP project, new devices and systems will be developed by the application partners in automotive and secure based on FD-SOI and embedded digital technology to answer specific applications needs.

Keywords: microcontrollers,pilot lines,non volatile memory,embedded flash technology,phase change memory,fdsoi,energy consumption